Literature DB >> 9128946

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

L Gaspar1, C Scott, M Rotman, S Asbell, T Phillips, T Wasserman, W G McKenna, R Byhardt.   

Abstract

PURPOSE: Promising results from new approaches such as radiosurgery or stereotactic surgery of brain metastases have recently been reported. Are these results due to the therapy alone or can the results be attributed in part to patient selection? An analysis of tumor/patient characteristics and treatment variables in previous Radiation Therapy Oncology Group (RTOG) brain metastases studies was considered necessary to fully evaluate the benefit of these new interventions. METHODS AND MATERIALS: The database included 1200 patients from three consecutive RTOG trials conducted between 1979 and 1993, which tested several different dose fractionation schemes and radiation sensitizers. Using recursive partitioning analysis (RPA), a statistical methodology which creates a regression tree according to prognostic significance, eighteen pretreatment characteristics and three treatment-related variables were analyzed.
RESULTS: According to the RPA tree the best survival (median: 7.1 months) was observed in patients < 65 years of age with a Karnofsky Performance Status (KPS) of at least 70, and a controlled primary tumor with the brain the only site of metastases. The worst survival (median: 2.3 months) was seen in patients with a KPS less than 70. All other patients had relatively minor differences in observed survival, with a median of 4.2 months.
CONCLUSIONS: Based on this analysis, we suggest the following three classes: Class 1: patients with KPS > or = 70, < 65 years of age with controlled primary and no extracranial metastases; Class 3: KPS < 70; Class 2- all others. Using these classes or stages, new treatment techniques can be tested on homogeneous patient groups.

Entities:  

Mesh:

Year:  1997        PMID: 9128946     DOI: 10.1016/s0360-3016(96)00619-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  675 in total

1.  Little response of cerebral metastasis from hepatocellular carcinoma to any treatments.

Authors:  Jung Ho Han; Dong Gyu Kim; Jung Cheol Park; Hyun-Tai Chung; Sun Ha Paek; Young Seob Chung
Journal:  J Korean Neurosurg Soc       Date:  2010-05-31

Review 2.  Management of brain metastasis: past lessons, modern management, and future considerations.

Authors:  Eugene Koay; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

3.  Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.

Authors:  Hee-Jun Kim; Seock-Ah Im; Bhumsuk Keam; Yu-Jung Kim; Sae-Won Han; Tae Min Kim; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Eui Kyu Chie; Wonshik Han; Dong-Wan Kim; Tae-You Kim; Dong-Young Noh; Dae Seog Heo; In Ae Park; Yung-Jue Bang; Sung Whan Ha
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

4.  Overview of the diagnosis and management of brain, spine, and meningeal metastases.

Authors:  G E Gerrard; K N Franks
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

5.  Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?

Authors:  C Nieder; N H Andratschke; O Spanne; H Geinitz; A L Grosu
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

6.  The role of radiosurgery in patients with brain metastasis from small cell lung carcinoma.

Authors:  Kwang Wook Jo; Doo Sik Kong; Do Hoon Lim; Yong Chan Ahn; Do-Hyun Nam; Jung-Il Lee
Journal:  J Korean Neurosurg Soc       Date:  2011-08-31

7.  Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival.

Authors:  Susanne Bartelt; Felix Momm; Christian Weissenberger; Johannes Lutterbach
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

Review 8.  Malignant germ cell tumors metastatic to the brain: a model for a curable neoplasm? The Freiburg experience and a review of the literature.

Authors:  Johannes Lutterbach; Uwe Spetzger; Susanne Bartelt; Axel Pagenstecher
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 9.  Temozolomide for treatment of brain metastases: A review of 21 clinical trials.

Authors:  Wei Zhu; Li Zhou; Jia-Qi Qian; Tian-Zhu Qiu; Yong-Qian Shu; Ping Liu
Journal:  World J Clin Oncol       Date:  2014-02-10

10.  Survival and recurrence for patients undergoing surgery of skull base intracranial metastases.

Authors:  Kaisorn L Chaichana; Mariana Flores; Shami Acharya; Paul Sampognaro; Chetan Bettegowda; Daniele Rigamonti; Jon D Weingart; Alessandro Olivi; Gary L Gallia; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa
Journal:  J Neurol Surg B Skull Base       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.